Next, we assessed the combination regimen of ASO with the several classic inhibitors (palbociclib, ribociclib, abemaciclib, fulvestrant, everolimus and tamoxifen) for ER+ breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.